Oculis Holding (OCS)

• Market cap: $1.59B
• 1 day: 0%
• 5 days: 4.09%
• 1 month: 1.66%
• 3 months: -5.34%
• 6 months: 41.07%
• Year to date: 37.4%
• 1 year: 54.99%
• 5 years: 152.34%
• 10 years: 152.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Employees: 60